Bio-Rad Slowly Re-enters Thermal Cycler Market, But Residual Legal Costs Expected to Impact Q1 | GenomeWeb

Bio-Rad officials said last week that even though the firm has recently settled its thermal cycler litigation with Applied Biosystems and Roche Molecular Systems, they expect to incur residual legal costs in the first quarter and experience a slow ramp-up in returning to that market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.